meningococcal vaccine GSK134612 + human papillomavirus vaccine

The combination of **meningococcal vaccine GSK134612** and **human papillomavirus vaccine** refers to a co-administration regimen developed by GSK, primarily evaluated in adolescent populations. The meningococcal component, **GSK134612** (marketed as **Menveo**), is a quadrivalent conjugate vaccine targeting *Neisseria meningitidis* serogroups A, C, W-135, and Y, with each capsular polysaccharide conjugated to a non-toxic mutant of diphtheria toxin (CRM197). The human papillomavirus component (marketed as **Cervarix**, code **GSK580299**) is a bivalent vaccine targeting oncogenic HPV types 16 and 18, utilizing recombinant L1 capsid proteins formulated as virus-like particles (VLPs) with the **AS04** adjuvant system (aluminum hydroxide and monophosphoryl lipid A). This combination has been investigated in Phase 3 clinical trials to demonstrate that simultaneous administration maintains the safety and immunogenicity profiles of both vaccines, thereby facilitating streamlined immunization schedules for the prevention of invasive meningococcal disease and HPV-related cancers.

Brand names

MenveoCervarix

Other names

MenACWY-CRM + HPV-16/18 vaccineQuadrivalent meningococcal conjugate vaccine + Bivalent HPV vaccine